#USA #Fort Lee #Mezzion Pharmaceuticals #Give Kids a Chance #Mikaela Naylon

Mezzion Pharmaceuticals Applauds New Pediatric Legislation

In a significant development for pediatric healthcare, Mezzion Pharmaceuticals has expressed its strong approval of the newly enacted Mikaela Naylon Give Kids a Chance Act. This important piece of legislation was signed into law by President Trump as part of the Consolidated Appropriations Act, 2026, and marks a major step forward in rallying support for children suffering from rare diseases.

The Give Kids a Chance Act reinstates the Rare Pediatric Disease Priority Review Voucher (PRV) program, which had been a cornerstone in expediting the development of medications designed specifically for pediatric conditions. By revitalizing this program, the act aims to enhance the landscape for pediatric drug development significantly, facilitating quicker access to life-saving therapies for our nation's youngest patients.

Dean Park, the Chairman and CEO of Mezzion Pharmaceuticals, underscored the importance of this legislation by stating, "This signing reinforces a national commitment to children and families living with rare diseases." He highlighted the necessity of continual innovation in medicines for pediatric patients, mentioning that Mezzion is actively working on bringing the first potential approved therapy for Fontan physiology — a condition associated with single ventricle congenital heart disease — to market. This charge is particularly crucial for communities that currently lack available treatment options.

Lingering challenges remain for children with rare diseases such as single ventricle congenital heart disease, which had a prominent presence during the discussions and lobbying efforts to restore the PRV program. Mezzion Pharmaceuticals played a critical advocacy role, while a patient representative directly brought the voices of those affected into the legislative process through congressional committee briefings and panels. This collaboration reflects a unified effort among stakeholders to drive policy changes aimed at improving health outcomes for children suffering from rare diseases.

Mezzion Pharmaceuticals has been at the forefront of these advocacy efforts through its participation in the Rare Disease Company Coalition. This coalition has been pivotal in promoting policies that not only recognize the unique challenges facing pediatric patients but also work towards solutions that enable faster availability of critical treatments.

About Mezzion Pharmaceuticals

Mezzion Pharmaceuticals, Inc., a U.S. subsidiary of Mezzion Pharma Co., Ltd., is dedicated to advancing therapies for rare and underserved diseases. The company is currently developing JURVIGO® (udenafil), which could be a pioneering treatment option for those with single ventricle congenital heart disease. Although JURVIGO is still in the investigational phase and has not yet received any regulatory approval, the company's commitment to improving the lives of patients with rare medical conditions remains unwavering.

In conclusion, the enactment of the Mikaela Naylon Give Kids a Chance Act, coupled with the strategic initiatives of Mezzion Pharmaceuticals and other advocates, heralds a more hopeful future for children afflicted by rare diseases. Both the healthcare community and families can look forward to new advancements in treatment opportunities that may soon be accessible to those who need them the most.